Abstract:Objective To compare the effect and safety of using Rivaroxaban to prevent deep venous thrombosis (DVT) at different time in the perioperative stage. Methods There were 150 hip replacement patients in our hospital from January 2014 to October 2016. Based on the admission criteria, they were randomly divided into 4 groups. The patients in the group A used Rivaroxaban 72 h before operation. The patients in the group B used Rivaroxaban 48 h prior to the surgery. The patients in the group C used Rivaroxaban 24 h in advance to the operation. The patients in the group D used Rivaroxaban 6 h before operation. The incidence of DVT and hemorrhagic complications in the 4 groups of patients were observed. The perioperative bleeding volume was also recorded. Results In the groups A,there was 1 case of DVT, and the incidence was 2.5%. In the group B, 4 cases had DVT, the incidence was 11.1%. In the group C, 5 cases had DVT, the incidence was 13.2%. In the group D, 11 cases had DVT, the incidence was 30.6%.The DVT incidence of the group A was obviously lower than those in the groups B, C and D, and the differences were statistically significant (P < 0.05). The amount of hemorrhage in the perioperative stage among the 4 groups had no statistical meaning (P > 0.05). Conclusions Using Rivaroxaban 72 h before operation has better effect and higher safety in the prevention of DVT after hip replacement.